On Mar. 17, 2020, MannKind announced it was adjusting research and development resources that were reserved for its pipeline of investigational products for treating serious lung diseases, with the goal of prioritizing work on new compounds that may have the potential to address the morbidity and mortality associated with respiratory viral infections, such as COVID-19.

Specifically, MannKind initiated a collaboration with Immix Biopharma, to prepare a dry powder formulation of a compound with the potential to treat acute respiratory distress syndrome, a complication of COVID-19.  The immediate focus of this effort was to rapidly develop prototype powders, which will then be assessed for their potential to be used therapeutically.  Other collaborations are being actively explored at this time.

MannKind is committed to joining the global effort to overcome the COVID-19 crisis.  MannKind’s formulation and drug development expertise as well as its excess manufacturing capacity were to be deployed as necessary to help protect humankind from this global health crisis.